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Single-stranded RNAs interact with components of the RNA interference pathway to reduce the
expression of targetmRNAs. Now, Lima et al. and Yu et al. show that, with extensive chemicalmodi-
fications, small single-stranded RNAs can robustly induce gene silencing with efficacy similar to
their double-stranded counterparts.Nucleic acids and chemical derivatives
synthesized as antisense oligonucleo-
tides (ASOs) or small interfering RNAs
(siRNAs) are used widely to reduce the
expression of target genes for functional
assays and therapeutic purposes. ASOs
are single-stranded oligonucleotides
designed to base-pair with target RNAs
and reduce their expression by trigger-
ing RNaseH-dependent or -independent
mechanisms (Bennett and Swayze,
2010) (Figure 1A). siRNAs are double-
stranded RNAs (dsRNAs) that engage
the endogenous RNA-induced silencing
complex (RISC) and repress expression
by base-pairing with and cleaving target
mRNAs via a mechanism that is depen-
dent on the cofactor Ago2 (Figure 1B)
(Davidson and McCray, 2011). Single-
stranded siRNAs (ss-siRNAs) also induce
gene silencing, but their potency is sig-
nificantly lower than that of their dsRNA
counterparts (siRNAs, short-hairpin
RNAs [shRNAs], or artificial microRNAs
[miRNAs]) (Schwarz et al., 2002). In this
issue of Cell, two studies (Lima et al.,
2012; Yu et al., 2012) show that chemical
modifications to the ss-siRNA dramati-
cally improve both potency and activity.
The ss-siRNA activity requires RNAi
pathway engagement and demonstrates
target gene silencing in liver (Lima et al.,
2012) and brain (Yu et al., 2012).
Endogenously expressed microRNAs
(miRNAs) typically inhibit the expression
of target mRNAs that contain sequences
complementary to bases 2–8 of the
antisense (or guide) strand of the miRNA
known as the seed region (Lewis et al.,
2005). Though siRNAs, shRNAs, andartificial miRNAs are intended to induce
target transcript cleavage via perfect
base-pairing, they can also mediate
silencing of off-target mRNAs by seed-
based recognition as with the canonical
miRNA-like mechanism (Birmingham
et al., 2006). And the sense strand, if
loaded into the RNAi machinery, can
behave similarly. This potential to induce
substantial off-target silencing and toxi-
city is obviated by the ss-siRNA design;
the sense strand does not exist. The anti-
sense strand can still pose this risk,
however, a concern that was not ad-
dressed in the current studies. Given the
high doses delivered for reduction of
target mRNAs in vivo, off-target gene
silencing via miRNA-like mechanisms
will require careful evaluation. For ex-
ample, the CAG-repeat-targeting con-
structs used by Corey and colleagues
(Yu et al., 2012), which show selectivity
for mutant huntingtin over wild-type
huntingtin, use ss-siRNAs with putative
seed sequences that could silence
numerous other transcripts that do not
necessarily contain the full complement
of the ss-siRNA.
A major advance toward the future
utility of ss-siRNAs comes from the
exhaustive investigation of numerous
modifications to the ss-siRNA design
and their impact on stability, pharmaco-
kinetics, and potency (Lima et al.,
2012). Of note, the authors confirm the
importance of the 50-phosphate for
activity (Schwarz et al., 2002) and identify
a stable 50-phosphate modification using
a 50-(E)-vinylphosphate. The ss-siRNAs
become associated with Ago2, andCell 15both studies show that the ss-siRNAs
require Ago2 for activity. In the work by
Crooke and colleagues (Lima et al.,
2012), the ss-siRNAs are fully comple-
mentary to the target sequences, and
Ago2 is required for cleavage. Intrigu-
ingly, Yu et al. (2012) design an ss-siRNA
with a single mismatch between the
target and the ss-siRNA, causing a bulge.
Again, Ago2 is required for activity, but
cleavage of the target transcript does
not occur; a bulge in the sequence prob-
ably inhibits this activity. Interestingly,
this form of translational repression
does not ultimately cause target destabi-
lization and a concomitant decrease in
transcript levels as found for most
mRNAs acted upon by endogenous
miRNAs (Guo et al., 2010). This may
reflect differences between miRNA-
mediated silencing by either exoge-
nously expressed miRNA sequences or
endogenously expressed miRNAs, which
most often occur via interactions with
30-untranslated regions (Birmingham
et al., 2006). The sequences employed
by Yu and colleagues (Yu et al., 2012)
target the first exon.
After testing of the ss-siRNAs in vitro,
their therapeutic utility is examined in vivo
against several targets in the liver (Lima
et al., 2012) or in the brain (Yu et al.,
2012). Potent gene silencing of Factor
VII, PTEN, and ApoCIII is observed with
ss-siRNAs in saline-based buffers in
contrast to the usual requirement for
lipid-based formulations for ds-siRNAs,
which can often cause toxicity. Silencing
activity is improved further by the addition
of a lipophilic moiety on an internal base,0, August 31, 2012 ª2012 Elsevier Inc. 873
Figure 1. Gene Silencing Approaches in Mammals
(A) Antisense oligonucleotides (ASO) are designed to bind and reduce the expression of a target RNA by: (1) activating RNaseH protein and inducing RNA
degradation or (2) acting as steric blockers and interfering with the maturation or translation of a target RNA.
(B) Small interfering RNAs (siRNAs) are designed to co-opt the RNA-induced silencing complex (RISC) of the endogenous RNA interference (RNAi) pathway to
reduce the expression of a target RNA. siRNAs can be designed as single-stranded (ss-siRNAs) or double-stranded RNAs (siRNAs). Alternatively, double-
stranded RNAs can be incorporated into expression vectors by embedding siRNA sequences into stem-loop structures designed to mimic endogenous primary
miRNA transcripts (artificial miRNAs) or pre-miRNAs (short-hairpin RNAs [shRNAs]). Artificial miRNAs and shRNAs are incorporated into the RNAi pathway before
or after the microprocessor complex stage (Drosha-DRG8 processing), respectively, and are then exported to the cytoplasm. For double-stranded siRNAs, one
of the two strands is degraded. ss-siRNAs are directly incorporated into the RISC complex.which improves serum stability and
uptake (Lima et al., 2012). The target
tested in the mouse central nervous
system (CNS) is mutant huntingtin, the
underlying cause of the fatal, autosomal-
dominant neurodegenerative disorder
Huntington’s disease (HD). The mutation,
a polyglutamine-coding repeat (>36
repeats) expansion in exon 1 of the hun-
tingtin mRNA, provides one avenue for
specific silencing of the disease allele
while leaving the wild-type allele, which
has fewer CAG repeats, intact. The thera-
peutic benefits of silencing mutant
huntingtin expression with ASOs and
inhibitory RNAs have been reported (Bou-
dreau et al., 2009; Kordasiewicz et al.,
2012) and are in preclinical testing. Yu
et al. (2012) revisit CAG repeat targeting
using ss-siRNAs harboring the chemical
modifications found by Crooke and
colleagues to improve in vivo stability
and activity (Lima et al., 2012) of
sequences previously tested as dsRNAs.874 Cell 150, August 31, 2012 ª2012 ElsevieInterestingly, the ss-siRNAs are more
potent than their ds-siRNA counterparts.
Similar to ASOs targeting huntingtin deliv-
ered into the mouse brain ventricles, the
ss-siRNAs distribute widely throughout
the brain and reduce mutant huntingtin
protein levels (Kordasiewicz et al., 2012),
but in this study, there is limited impact
on the levels of wild-type protein. One
caveat with the in vivo selectivity assay
revolves around the fact that, with respect
tohumansequence that contains astretch
of 10 to 29 CAG repeats, the 7-glutamine
repeat in exon 1 of the normal mouse
allele is not encoded by a pure CAG
repeat. Thus, the additional mismatch
between the wild-type allele and the ss-
siRNA could contribute to the enhanced
selectivity of silencing in vivo.
Repetitive dosing of the ss-siRNAs to
liver does not increase liver enzymes
associated with hepatocellular toxicity.
Similar assessments in the brain were
not done. Given the doses applied tor Inc.the CNS (10 mg/kg per day for 28 days)
and the fact that ss-siRNAs engage the
RNAi machinery, careful toxicity studies
will be required in future work. Potential
saturation of the RISC by ss-siRNAs,
which in the setting of siRNA or ex-
pressed shRNAs and miRNAs can
reduce the proper processing and activity
of endogenous miRNAs, will also be
important to investigate. The association
of ss-siRNAs with Ago2 (and presumably
the other Agos) may impact the normal
function of these proteins in cells. As
noted by Corey and colleagues, it
will be difficult to infer the toxicity and
off-target impact from their ds-siRNA
counterparts, and thus directed studies
on the ss-siRNAs themselves will be
important.
In summary, these studies introduce
ss-siRNAs as an exciting new tool in our
arsenal to silence disease-causing genes
for therapeutic applications and basic
research. It is also possible, given their
stability and ability to enter cells without
lipid formulation, that they may find utility
as a sponge for disease-related miRNAs.
Given the noted tolerance of the liver
to high doses of the ss-siRNAs, they
could conceivably be used to inhibit
miRNAs involved in disease pathogen-
esis. Indeed, tiny locked nucleic acids
(LNAs) with complementarity to miRNAs
show promise in reducing miRNA activity
(Obad et al., 2011).
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Histone methylation is widely believed to contribute to epigenetic inheritance by persevering
through DNA replication and subsequently templating methylation of daughter chromosome
regions. However, a report in this issue (Petruk et al.) suggests that chromatin association of the
methytransferase complexes themselves persists through replication and re-establishes histone
methylation.Epigenetics is the study of heritable
changes in gene expression caused by
mechanisms other than changes in the
underlying DNA sequence. Epigenetic
inheritance of specific patterns of gene
expression is essential for the mainte-
nance of cell lineages. Large multiprotein
complexes and posttranslational modifi-
cations of histone proteins that package
DNA have been linked to both the active
expression and repression of genes
that define particular cell types. However,
the mechanism by which this protein
architecture is manipulated to allow the
replication machinery to pass by butremember its original configuration for
reassembly has been a topic of much
study and debate. Covalent histone
modifications have been implicated in
epigenetic inheritance in numerous
studies (Suganuma and Workman, 2011;
Zhu and Reinberg, 2011), and it has
been proposed that these modifications
are maintained at specific genomic loci
through mitotic cell divisions. A model
has emerged in which modified histones
on parental DNA are randomly partitioned
to daughter strands during DNA replica-
tion and subsequently promote the modi-
fication of newly added histones. Thismechanism would ensure that the archi-
tecture of specific loci is passed on
to daughter cells (Corpet and Almouzni,
2009; Zhu and Reinberg, 2011). A provoc-
ative report now challenges, or at
least provides a dramatic alternative
to, this model. Petruk et al. (2012) pre-
sent evidence from Drosophila embryos
that histone modifications are actually
lost during DNA synthesis and, instead,
that the association of histone-modifying
enzyme complexes with specific loci
persists during replication and re-estab-
lishes the histone modifications after S
phase.0, August 31, 2012 ª2012 Elsevier Inc. 875
